2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 507

Echocardiographic Markers of Right Ventricle Dysfunction in Hispanic Patients with Rheumatoid Arthritis: A Case-Control Study
Abstract Number: 2096

Ectonucleotidase CD73 Suppresses Autoantibody Production and Arterial Vasculopathy in Murine Lupus
Abstract Number: 1471

ECV304 Cells Self-Citrullinate Proteins Targeted By Anti-Citrullinated Protein/Peptide Autoantibodies from Rheumatoid Arthritis Patients
Abstract Number: 2035

Effect of Baricitinib on Joint-Related Biomarkers in Patients with Moderate-to-Severe Rheumatoid Arthritis
Abstract Number: 2484

Effect of Biologic Agents on Synovial Tissues from Patients with Rheumatoid Arthritis
Abstract Number: 702

Effect of Biologics on Radiographic Progression of Peripheral Joints in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Abstract Number: 2540

Effect of Buccal Hygiene on the Systemic Activity of Patients with Rheumatoid Arthritis: A Randomized Clinical Trial
Abstract Number: 419

Effect of Changes in Physical Activity on Cartilage Degradation in Knee Osteoarthritis
Abstract Number: 1276

Effect of Colchicine on Diabetes Incidence Among Gout Patients in a Veterans’ Affairs Population
Abstract Number: 1988

Effect of Different Fucoidans on Pathological Pathways Activated in Osteoarthritic Chondrocytes and Synoviocytes
Abstract Number: 578

Effect of Disease Duration and Other Patient Baseline Characteristics on Outcomes in Tocilizumab-Treated Rheumatoid Arthritis Patients: A Pooled Analysis
Abstract Number: 1525

Effect of JAK-Inhibitor Versus Bdmards on Quality of Life in Rheumatoid Arthritis : A Meta Analysis of Randomized Controlled Trials
Abstract Number: 456

Effect of Local and Systemic CCR2 Blockade on Knee Hyperalgesia in a Mouse Model of Osteoarthritis
Abstract Number: 1226

Effect of New Method for Pre-Administration Assessment of Intravenous Biologics on Infections in Patients with Rheumatoid Arthritis
Abstract Number: 2759

Effect of Specific Treatments on Clinical, Serologic, and Imaging Assessments of Disease Activity in Large-Vessel Vasculitis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].